Last Updated: 18/06/2024
Development of a potent and fast acting antimalarial that is orally efficacious in vivo
Objectives
To develop a potent and fast acting antimalarial that is orally efficacious in vivo.
Principal Institution
Walter and Eliza Hall Institute of Medical Research (WEHI), Australia
Principal Investigators / Focal Persons
Rationale and Abstract
Malaria is a devastating disease that causes 420,000 deaths worldwide annually. Critically malaria parasites have become resistant to nearly all currently used drug classes, and therefore there is an urgent need to develop new therapies. A highly active antimalarial class with a known mechanism of action has been identified and all the prerequisites required to advance this antimalarial class into human clinic trials in partnership with Medicines for Malaria Venture and Janssen Pharmaceuticals.
Date
Dec 2021
Total Project Funding
$752,667
Funding Details
Country / Project Site(s)
Related Resources
